Clinical Trials – Gdansk, Poland

PI-House Clinical Trial Center

Site in Gdańsk, acting under the brand of PI House, became a part of Penta Hospitals Poland in mid-2024. It has been operating for many years, becoming a specialized research center, focused on developing therapies in psychiatry, neurology, dermatology, metabolic diseases, and rheumatology.

For over a decade, we have completed over 250 clinical trials at the Gdańsk Clinical Research Center. Together with a team of 35 experienced and dedicated specialists, we conduct approximately 60 active research projects annually, combining clinical expertise with attentiveness to participants’ needs.

As one of the most experienced sites in Poland specializing in trials in the area of a central nervous system (CNS), since 2011 we have been a trusted partner for pharmaceutic companies, CROs, and patients.

We conduct clinical trials in the following therapeutic areas:

  • Adult Psychiatry;
  • Child and Adolescent Psychiatry;
  • Neurology;
  • Adult Dermatology;
  • Child and Adolescent Dermatology;
  • Metabolic Disorders;
  • Rheumatology.

As the first private site in Poland, we have started trials using control substances, including psychedelic substances — in a dedicated to that therapeutic space, in compliance with ethical and regulatory requirements.

In January 2026, the PI-House Clinical Research Center expanded its operations by opening a new branch at ul. Wyspiańskiego 25 (80-434 Gdańsk), established in cooperation with the NeuroVitalis clinic. This expansion forms part of a long-term strategy to develop research infrastructure and strengthen expertise in the fields of neurology, psychiatry, and pain management. The new location enables the implementation of clinical projects on a larger scale, including new indications such as multiple sclerosis and Parkinson’s disease, while maintaining full operational oversight, high quality standards, and regulatory compliance.

 

Badania kliniczne Gdańsk | Penta Hospitals Badania Kliniczne

Address:

ul. Na Zaspę 3,
80-546, Gdańsk
Zobacz w Google Maps

Contact Hours:

Pon-pt: 7:00 – 18:00

Check the location of our center

Buses

148 – Żabianka SKM to Zajezdnia Nowy Port
283 – Niedźwiednik to Zajezdnia Nowy Port

Trams

5 – Strzyża PKM to Zajezdnia Nowy Port
7 – Łostowice to Zajezdnia Nowy Port
10 – Brętowo to Zajezdnia Nowy Port

Railway

SKM Żabianka – then take a bus 148 Żabianka SKM to Zajezdnia Nowy Port

We carry out clinical trials in the following therapeutic areas:

As the first private site in Poland, we have started trials using control substances, including psychedelic substances — in a dedicated to that therapeutic space, in compliance with ethical and regulatory requirements.

Center Infrastructure:

PI-House has infrastructure designed specifically for demanding research projects:

Laboratorium snu

Sleep laboratory

(2 stanowiska polisomnografii)

Strefa całodobowego pobytu

24-hour stay area

dla uczestników badań klinicznych

W pełni wyposażone gabinety lekarskie i diagnostyczne

Specialized space for psychedelic research

Nowoczesne sale konsultacyjne

Modern Consultation Rooms

for physicians and patients

Pomieszczenia dla zespołu monitorującego i koordynatorów

Rooms for the monitoring team and coordinators

Zaawansowane systemy ciągłego monitorowania temperatury

Advanced systems of continuous temperature monitoring

Bezpieczne strefy przechowywania IMP

Safe IMP storage zones

ze szczególnym uwzględnieniem procedur związanych z obiegiem substancji kontrolowanej w ramach ośrodka.

The center meets the highest storage standards, and restricted access to the Investigational Product ensures full control over research products. All facilities are adapted to the requirements of GCP (Good Clinical Practice)–compliant clinical trials and provide comfort and safety for participants.

Our Specialists:

Our greatest asset is an experienced and dedicated team.

Our staff consists of seasoned specialists who combine clinical expertise with proficiency in conducting clinical trials in accordance with GCP (Good Clinical Practice) and international standards.

Doctors

specializing in psychiatry, neurology, dermatology, diabetology, geriatrics, and rheumatology;

Psychotherapists

trained to work with controlled substances, specifically with psychedelics;

Coordinators

clinical trial coordinators with many years of experience in managing documentation, study schedules, and participant care;

Nurses and Pharmacists

Qualified nursing staff and pharmacists trained in clinical protocols and participant safety.

Quality Control:

Our operational structure is based on clearly defined processes that comply with international GCP standards. A strong focus on quality is the foundation of our clinical trials, ensuring full data integrity and patient safety.

Quality Specialist

Supervision of quality processes is carried out by a qualified specialist responsible for monitoring compliance with international standards, conducting internal audits, and coordinating corrective actions.

Process Management System

We implement a comprehensive process management system that enables precise mapping and monitoring of all activities related to clinical trials. This ensures full compliance with internal procedures and high operational efficiency.

Internal Training

We regularly conduct specialized quality training to ensure that all members of our team are up to date with the latest requirements and best practices in quality management.

Standard Operating Procedures (SOPs)

At Penta Hospitals Poland, every activity—regardless of its scale—is precisely defined within the Standard Operating Procedures (SOPs). These documents are regularly updated to meet evolving regulatory requirements, ensuring operational continuity and consistency at every stage of clinical trial execution.

List of Clinical Trials
Conducted at the Center

Clinical trials – Atopic dermatitis in adults

Atopic dermatitis is a condition that can impact the comfort of daily life. Unesthetic redness can affect the sick person's appearance, which can lead to lower self-esteem.

Clinical trials – Psoriasis

Psoriasis is a chronic, autoimmune disease with symptoms of numerous dermatological changes, with periodic remissions and exacerbations.

Diabetes
Recruiting trial

Diabetes

Diabetes is a chronic disease of a metabolic character, also called mellitus. Its direct cause is an incorrect glucose metabolism in blood.

Clinical trials – Depression

Depression is a common mental health disorder classified as a mood disorder. It is characterized by persistent sadness and/or an inability to experience pleasure. It also alters sleep and appetite, increases fatigue, and impairs concentration.

Clinical trials – Obesity

Persons who are overweight or suffer from obesity and other coexisting diseases, e.g. cardiovascular diseases, diseases of a circulatory system, knee joint degeneration.

Clinical trials – Alzheimer’s disease

Alzheimer's disease is a degenerative brain condition whose symptoms include progressive memory and behavioural disorders that, over time, completely prevent the patient from correct functioning in everyday life.

Schizophrenia
Recruiting trial

Schizophrenia

Schizophrenia is a mental illness that belongs to psychotic disorders. It involved an inadequate perception, reception, and evaluation of reality.

Clinical trials – Peripheral neuropathy

Peripheral neuropathy is a condition that can significantly impact daily functioning, causing pain, numbness, and muscle weakness. Early diagnosis and proper treatment can slow the progression of the disease and improve the standard of life.

Clinical trials – stage 1 and 2 hypertension

Hypertension is a frequently experienced health problem, which can leave no symptoms for a long time, and still increase the risk of serious heart, brain, and kidney diseases. Early diagnosis and proper control of hypertension allow to significantly reduce the risk.

Pustular psoriasis of the hands and feet

This is a rare form of psoriasis characterized by the presence of sterile pustules, redness, and painful inflammatory lesions affecting the hands and feet. The condition is inflammatory in nature and typically follows a course marked by periods of exacerbation and remission.

AD is a problem experienced both by adults and children. According to epidemiology statistics, persons under 18 experience this disease almost 10 time more often than adults.

Trial in progress

Clinical trials – Acne

Acne is a common skin condition experienced by both teenagers and adults. It is characterized by blackheads, papules, pustules and purulent cysts, mainly on the face, neck, arms, upper back and chest.

Migraine is categorized as a so-called primary headaches, meaning those that do not result from other underlying medical conditions. It is characterized by the recurrence of headaches, sometimes accompanied by additional neurological symptoms.

Sleep disorders can involve abnormal sleep duration or undesirable behaviours when sleeping. This is a serious clinical problem that impacts the patients’ daily functioning, sometimes preventing them from conducting normal life activities.

Children’s autism is a complex disorder of development and the functioning of central nervous system, characterized by disruptions in the ability to communicate feelings and build interpersonal relationships.

For many people taking antidepressants doesn’t give desired results. A patient condition in which two or more antidepressants have proven ineffective is sometimes called treatment-resistant depression (TRD).

This disease causes stigmatization and leads to different bothersome symptoms, such as itching, burning, sometimes even pain.

Childhood psoriasis, similarly to adult psoriasis, is a chronic, autoimmune disease with periodic remissions and exacerbations.

Alopecia areata is a condition leading to localized hair loss, most commonly affecting adult women and men, but also it might also be experienced by children and adolescents. The condition is characterized by sudden hair loss, usually in oval or circular patches.

Program directed to children and teenagers of 6 to 18 years of age with diagnosed alopecia areata

Psoriatic arthritis is an inflammatory joint disease that occurs in the course of psoriasis. It belongs to seronegative spondyloarthropathies. It often begins in the interphalangeal joints and often affects only one side.

Nonspecific back pain is a medical term that describes back pain whose cause cannot be clearly identified using standard imaging tests, such as X-rays or MRIs. This means that although the patient experiences the pain, the specific underlying disease or injury cannot be identified.

Rheumatoid arthritis is a systemic connective tissue disease characterized by symmetrical, non-specific joint inflammation. It is also accompanied by extra-articular symptoms and systemic complications. Rheumatoid arthritis has a progressive course and, if left untreated, inevitably leads to disability.

Hives is a skin condition characterized by specific wheals, redness, and itching. Hives is often accompanied by swelling known as angioedema.

Diabetic neuropathy is the most common complication of diabetes. It brings damage to peripheral nerves caused by excessively high blood glucose levels.

Vitiligo is a chronic skin disease characterized by the loss of pigment in the skin, leading to the formation of white patches.

Completed trial

Dyslipidaemia

Dyslipidaemia is a metabolic disorder affecting lipid metabolism. Abnormalities affect the concentration, composition, and function of individual lipids and lipoproteins in plasma.

Lifestyle influences liver health; being overweight and obese can contribute to the development of fatty liver disease, just as the lack of physical activity and taking certain medications (including sedatives, painkillers and hormonal drugs).

Nonalcoholic steatohepatitis is the most serious form of non-alcoholic fatty liver disease

It is a form of schizophrenia which begins earlier than in typical cases. Children’s schizophrenia is characterized by distorted thinking, emotions, and behaviour, which can significantly affect child’s daily functioning.

Borderline personality disorder, also known as borderline pattern personality disorder, is one of two subtypes of emotionally unstable personality disorder, along with the impulsive subtype.

Osteoarthritis of the knee joint is a chronic and progressive process of destruction of the normal structure of the joint, which included the degeneration of the cartilage, subchondral bone, ligaments, joint capsule, and other elements that make up the joint.

How to participate
in clinical trials

Step 1

Registration

Do you want to participate in a clinical trial? It’s simple. You just need to fill in a short registration form. Our team will contact you for an initial interview to check if the trial is suitable for you. Don’t worry, we will answer all your questions!

Step 2

Appointment with a doctor

After the initial qualification, we will invite you for an appointment with a doctor conducting the trial. The doctor will be available for you to tell you more about the trail, discuss any possible doubts and check the condition of your health.
The appointment is free-of-charge and non-committal.

Step 3

Decision

You are completely free to make your own decision about participating in the trial. After the meeting, you will have time to think through all the information. If you decide to participate, we will sign suitable documents and get you ready for next steps.

Step 4

Participation in the trial

After you make a decision, the actual part of the trial starts. You can always count on our support and use regular consultations.

Clinical Trial
Coordinators
in Gdańsk

Default Avatar

Kinga Rzeszkowska

Manager ds. Badań Klinicznych
Default Avatar

Patrycja Markiewicz

Senior Coordinator/CNS Area
Default Avatar

Stella Grodzicka

Senior Coordinator/Dermatology Area
Default Avatar

Julia Falkowska

Senior Coordinator/Diabetology, Rheumatology Area

Didn’t Find
a Clinical Trial You’re Interested In?

Contact us

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